dosulepin hydrochloride
dosulepin hydrochloride
CLINICAL USE
Tricyclic antidepressant
DOSE IN NORMAL RENAL FUNCTION
50–225 mg daily
PHARMACOKINETICS
Molecular weight                           :331.9 %Protein binding                           :84 %Excreted unchanged in urine     : 56 (mainly as metabolites) Volume of distribution (L/kg)       :45half-life – normal/ESRD (hrs)      :14–24/– DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function 10 to 20     : Start with small dose, and titrate according to response <10           : Start with small dose, and titrate according to response DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Not dialysed. Dose as in GFR <10 mL/min HD                     :Not dialysed. Dose as in GFR <10 mL/min HDF/high flux   :Unknown dialysability. Dose as in GFR <10 mL/minCAV/VVHD      :Unknown dialysability. Dose as in GFR 10 to 20 mL/min IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsAlcohol: increased sedative effect Analgesics: increased risk of CNS toxicity with tramadol; possibly increased risk of side effects with nefopam; possibly increased sedative effects with opioidsAnti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone – avoid concomitant use; increased risk of ventricular arrhythmias with drugs that prolong the QT interval; increased risk of arrhythmias with propafenoneAntibacterials: increased risk of ventricular arrhythmias with moxifloxacin – avoid concomitant use; concentration reduced by rifampicinAnticoagulants: may alter anticoagulant effect of coumarinsAntidepressants: enhanced CNS excitation and hypertension with MAOIs and moclobemide – avoid concomitant use; concentration possibly increased with SSRIsAnti-epileptics: convulsive threshold lowered; concentration reduced by carbamazepine, primidone, barbiturates and possibly phenytoinAntimalarials: avoid concomitant use with artemether/lumefantrineAntipsychotics: increased risk of ventricular arrhythmias especially with pimozide; increased antimuscarinic effects with clozapine and phenothiazines; concentration increased by antipsychoticsAntivirals: increased tricyclic side effects with amprenavir; concentration possibly increased with ritonavirAtomoxetine: increased risk of ventricular arrhythmias and possibly convulsionsBeta-blockers: increased risk of ventricular arrhythmias with sotalolClonidine: tricyclics antagonise hypotensive effect; increased risk of hypertension on clonidine withdrawalDopaminergics: avoid use with entacapone; CNS toxicity reported with selegiline and rasagiline Pentamidine: increased risk of ventricular arrhythmiasSibutramine: increased risk of CNS toxicity – avoid concomitant use. Sympathomimetics: increased risk of hypertension and arrhythmias with adrenaline and noradrenaline; metabolism possibly inhibited by methylphenidate ADMINISTRATION
Reconstition
– Route
Oral Rate of Administration
–Comments
–dosulepin hydrochloride (dothiepin).DOSULePIN HYDROCHLORIDe (DOtHIePIN) 251 OTHER INFORMATION
Metabolites are active and partly renally excretedMetabolites accumulate and cause excessive sedation25–50 mg usually effective without too much sedation.
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home